# US 2021/0079097 A1 · Pd-l1-binding molecules comprising shiga toxin a subunit scaffolds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079097 A1
- Document ID: US20210079097A1
- Status: Published application
- Kind: A1
- Application number: 17/025,729
- Filed: 2020-09-18
- Published: 2021-03-18
- Earliest claimed: 2019-09-18
- Assignees: Molecular Templates, Inc.
- Applicants: Molecular Templates, Inc.
- Inventors: Eric Poma; Hilario Ramos; Erin Willert; Richard Shimkets; Crystal Jackson; Thomas Vincent
- Web page: https://patentgrep.com/patent/US20210079097A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 39/12: Viral antigens
- A61P 35/00: Antineoplastic agents
- C07K 14/005: from viruses
- C07K 14/25: Shigella (G)
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 9/2497: {hydrolysing N- glycosyl compounds (3.2.2)}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6056: {Antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/53: Hinge
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).

## Claims

### Claim at position 1

-64. (canceled)

### Claim 65

A method of treating a disease, disorder, or condition in a subject, the method comprising a step of administering to a subject in need thereof a therapeutically effective amount of a PD-L1 binding molecule comprising a Shiga toxin effector polypeptide and a binding region capable of specifically binding an extracellular part of PD-L1;
wherein the binding region comprises:
(a) a heavy chain variable region (VH) comprising:
(i) a CDR1 comprising the amino acid sequence EYTMH (SEQ ID NO:27),
(ii) a CDR2 comprising the amino acid sequence GINPNNGGTWYNQKFKG (SEQ ID NO:29), and
(iii) a CDR3 comprising the amino acid sequence PYYYGSREDYFDY (SEQ ID NO:32); and
(b) a light chain variable region (VL) comprising:
(i) a CDR1 comprising the amino acid sequence SASSSVSYMY (SEQ ID NO:19),
(ii) a CDR2 comprising the amino acid sequence LTSNLAS (SEQ ID NO:20), and
(iii) a CDR3 comprising the amino acid sequence QQWSSNPPT (SEQ ID NO:26).

### Claim 66 (depends on 65)

The method of claim 65, wherein the Shiga toxin effector polypeptide comprises the sequence of SEQ ID NO: 41, or a sequence at least 90% identical thereto.

### Claim 67 (depends on 65)

The method of claim 65, wherein the VH comprises the sequence of SEQ ID NO: 34.

### Claim 68 (depends on 65)

The method of claim 65, wherein the VL comprises the sequence of SEQ ID NO: 35.

### Claim 69 (depends on 65)

The method of claim 65, wherein the VH comprises the sequence of SEQ ID NO: 34 and the VL comprises the sequence of SEQ ID NO: 35.

### Claim 70 (depends on 65)

The method of claim 65, wherein the binding region comprises a scFv linker that links the VH and the VL.

### Claim 71 (depends on 70)

The method of claim 70, wherein the scFv linker comprises the sequence of SEQ ID NO: 72.

### Claim 72 (depends on 65)

The method of claim 65, wherein the binding region is a single chain variable fragment (scFv).

### Claim 73 (depends on 65)

The method of claim 65, wherein the binding region comprises the sequence of SEQ ID NO: 106, or a sequence at least 90% identical thereto.

### Claim 74 (depends on 65)

The method of claim 65, wherein the PD-L1 binding molecule comprises a binding domain linker which links the Shiga toxin effector polypeptide and the binding region.

### Claim 75 (depends on 74)

The method of claim 74, wherein the binding domain linker comprises the sequence of SEQ ID NO: 73.

### Claim 76 (depends on 74)

The method of claim 74, wherein the binding molecule comprises, from N-terminus to C-terminus, the Shiga toxin effector polypeptide, the binding domain linker, the VH, and the VL.

### Claim 77 (depends on 65)

The method of claim 65, wherein the PD-L1 binding molecule comprises a CD8+ T-cell epitope that is heterologous to Shiga toxin A subunits.

### Claim 78 (depends on 77)

The method of claim 77, wherein the CD8+ T-cell epitope comprises the sequence NLVPMVATV (SEQ ID NO: 78).

### Claim 79 (depends on 77)

The method of claim 77, wherein the CD8+ T-cell epitope is linked to the binding region via a spacer.

### Claim 80 (depends on 79)

The method of claim 79, wherein the spacer has the sequence HHAA (SEQ ID NO: 265).

### Claim 81 (depends on 77)

The molecule of claim 77, wherein the binding molecule comprises, from N-terminus to C-terminus, the Shiga toxin effector polypeptide, the binding domain linker, the VH, the scFv linker, the VL, and the CD8+ T-cell epitope.

### Claim 82 (depends on 65)

The method of claim 65, wherein the PD-L1 binding molecule comprises the sequence of SEQ ID NO: 128, or a sequence at least 90% identical thereto.

### Claim 83 (depends on 65)

The PD-L1 binding molecule of claim 65, wherein the PD-L1 binding molecule is a single continuous polypeptide.

### Claim 84 (depends on 65)

The method of claim 65, wherein the PD-L1 binding molecule comprises two polypeptides.

### Claim 85 (depends on 84)

The method of claim 84, wherein each of the two polypeptides comprises the sequence of SEQ ID NO: 128.

### Claim 86 (depends on 84)

The method of claim 84, wherein the two polypeptides are non-covalently linked to each other.

### Claim 87 (depends on 84)

The method of claim 84, wherein the two polypeptides are linked to each other via the binding region.

### Claim 88 (depends on 65)

The method of claim 65, wherein the binding molecule is cytotoxic.

### Claim 89 (depends on 65)

The method of claim 65, wherein the binding molecule is non-cytotoxic.

### Claim 90 (depends on 65)

The method of claim 65, wherein the disease, disorder, or condition is an immune disorder or microbial infection.

### Claim 91 (depends on 65)

The method of claim 65, wherein the disease, disorder, or condition is cancer.

### Claim 92 (depends on 91)

The method of claim 91, wherein the cancer is characterized by a high mutational burden and/or a high frequency of indels.

### Claim 93 (depends on 91)

The method of claim 91, wherein the cancer is a solid tumor.

### Claim 94 (depends on 91)

The method of claim 91, wherein the cancer is bladder cancer, breast cancer, colon cancer, endometrial cancer, esophageal cancer, fallopian tube cancer, gastrointestinal cancer, glioma, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, Merkel cell carcinoma, mesothelioma, myeloma, nasopharyngeal neoplasm, ovarian cancer, pancreatic cancer, peritoneal neoplasm, prostate cancer, skin cancer, transitional cell carcinoma, or urothelial cancer.

### Claim 95 (depends on 91)

The method of claim 91, wherein the cancer is bladder cancer, and the bladder cancer is urothelial carcinoma.

### Claim 96 (depends on 91)

The method of claim 91, wherein the cancer is breast cancer, and the breast cancer is HER2 positive breast cancer or triple negative breast cancer.

### Claim 97 (depends on 91)

The method of claim 91, wherein the cancer is colon cancer, and the colon cancer is colorectal cancer.

### Claim 98 (depends on 91)

The method of claim 91, wherein the cancer is gastrointestinal cancer, and the gastrointestinal cancer is gastric cancer, biliary tract neoplasm, or gastroesophageal junction cancer.

### Claim 99 (depends on 91)

The method of claim 91, wherein the cancer is glioma, and the glioma is glioblastoma.

### Claim 100 (depends on 91)

The method of claim 91, wherein the cancer is head and neck cancer, and the head and neck cancer is squamous cell carcinoma of the head and neck.

### Claim 101 (depends on 91)

The method of claim 91, wherein the cancer is kidney cancer, and the kidney cancer is renal cell carcinoma.

### Claim 102 (depends on 91)

The method of claim 91, wherein the cancer is liver cancer, and the liver cancer is hepatocellular carcinoma.

### Claim 103 (depends on 91)

The method of claim 91, wherein the cancer is lung cancer, and the lung cancer is non-small cell lung cancer or small-cell lung cancer.

### Claim 104 (depends on 91)

The method of claim 91, wherein the cancer is lymphoma, and the lymphoma is Hodgkin lymphoma, non-Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, or diffuse large B-cell lymphoma.

### Claim 105 (depends on 91)

The method of claim 91, wherein the cancer is mesothelioma, and the mesothelial carcinoma is pleural mesothelioma.

### Claim 106 (depends on 91)

The method of claim 91, wherein the cancer is myeloma, and the myeloma is multiple myeloma.

### Claim 107 (depends on 91)

The method of claim 91, wherein the cancer is skin cancer, and the skin cancer is squamous cell cancer of the skin or melanoma.

### Claim 108 (depends on 91)

The method of claim 91, wherein the cancer is relapsed or refractory to treatment with at least one of ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, tremelimumab and cemiplimab.

### Claim 109 (depends on 91)

The method of claim 91, wherein the cancer is metastatic.
